Abbott Launches Next-Generation Oncodetect Test For Cancer Residual Disease Detection RTT News 15:17 Mon, 26 Oct
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment Abbott Laboratories (Press Release) 13:08 Mon, 26 Oct
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer Abbott Laboratories (Press Release) 14:15 Fri, 23 Oct
Abbott Laboratories vs. Unitedhealth: Does health innovation or health insurance make for a better stock to buy? The Motley Fool 18:37 Sat, 24 Oct All sources
Abbott launches next-generation Oncodetect test for cancer residual disease detection RTT News 15:17 Mon, 26 Oct Oncodetect Biotech Pharma
Dundee biotech PhaSER wins $2.7M Gates grant for infectious disease drugs The Next Web 6h Biotechnology Pharma Technology
Vir Biotechnology announces expanded Phase 2 solstice data for elebsiran and tobevibart in chronic Hepatitis Delta, showing deep and sustained viral suppression, and exploratory finite treatment data Business Wire (Press Release) 17h Biotechnology
Vir Biotechnology announces primary endpoint met in pivotal Phase 3 ECLIPSE 1 trial for elebsiran and tobevibart in chronic Hepatitis Delta Business Wire (Press Release) 18h Biotechnology
'Multi-node supply chains' are the future, in a 'multi-polar pharma world' The Loadstar 2h Biotechnology Article paywall
